

# TABLE OF CONTENTS

<b>0. Executive Summary .....</b>	<b>9</b>
<b>1. Introduction .....</b>	<b>11</b>
<b>Definitions .....</b>	<b>11</b>
<b>Historical Landmarks in the development of TDM .....</b>	<b>11</b>
<b>Pharmacology relevant to TDM .....</b>	<b>12</b>
Pharmacokinetics .....	12
Pharmacodynamics .....	13
Pharmacogenetics .....	13
Pharmacogenomics .....	13
Pharmacoproteomics .....	13
Drug receptors .....	13
Protein binding .....	14
<b>Therapeutic range of a drug.....</b>	<b>14</b>
<b>Variables that affect TDM.....</b>	<b>14</b>
<b>Indications for TDM .....</b>	<b>14</b>
<b>Multidisciplinary nature of TDM .....</b>	<b>16</b>
<b>2. Technologies for TDM .....</b>	<b>19</b>
<b>Introduction .....</b>	<b>19</b>
<b>Sample preparation .....</b>	<b>19</b>
<b>Proteomic technologies .....</b>	<b>19</b>
Mass spectrometry .....	19
<i>Liquid chromatography MS.....</i>	<i>19</i>
<i>Matrix-Assisted Laser Desorption/Ionization Mass Spectrometry .....</i>	<i>20</i>
<i>Combining capillary electrophoresis with MS.....</i>	<i>20</i>
<i>Gas-liquid chromatography .....</i>	<i>20</i>
<i>Tissue imaging mass spectrometry.....</i>	<i>20</i>
<i>New trends in sample preparation.....</i>	<i>21</i>
<i>Pressure Cycling Technology .....</i>	<i>21</i>
Desorption electrospray ionization imaging .....	22
<i>Analysis of dried blood spots for drugs using DESI .....</i>	<i>22</i>
High Performance Liquid Chromatography (HPLC) .....	22
<i>Ultra performance LC .....</i>	<i>23</i>
Paper spray.....	23
<i>Quantitative analysis of drugs in dried blood spot by paper spray MS .....</i>	<i>23</i>
<b>Immunoassays .....</b>	<b>23</b>
Enzyme-linked immunosorbent assay .....	24
Cloned Enzyme Donor Immunoassay.....	24
Enzyme Multiplied Immunoassay Technique .....	24
Fluorescence Polarization Immunoassay .....	25
Particle Enhanced Turbidimetric Inhibition Immunoassay .....	25
Radioimmunoassay .....	25
<b>Biosensors .....</b>	<b>26</b>
Nanosensors .....	26
<b>Biochips &amp; Microarrays .....</b>	<b>27</b>
Introduction .....	27
Microchip capillary electrophoresis .....	27
Phototransistor biochip biosensor.....	27
Cellular microarrays .....	28
Microfluidics for TDM .....	28
<i>Lab-on-a-chip.....</i>	<i>28</i>
<i>Micronics' microfluidic technology.....</i>	<i>29</i>
<i>Rheonix CARD technology .....</i>	<i>29</i>
<i>Nano-interface in a microfluidic chip.....</i>	<i>29</i>
<i>Levitation of nanofluidic drops with physical forces.....</i>	<i>30</i>
Nanoarrays .....	30
<b>Nanobiotechnology .....</b>	<b>31</b>
NanoDx™ .....	31
<b>Biomarkers .....</b>	<b>31</b>
Applications of biomarkers in drug safety studies .....	32
Genomic technologies for toxicology biomarkers .....	32
Proteomic technologies for toxicology biomarkers .....	33
Metabonomic technologies for toxicology biomarkers.....	33
Integration of genomic and metabonomic data to develop toxicity biomarkers.....	33
Toxicology studies based on biomarkers .....	33
<i>Biomarkers of hepatotoxicity .....</i>	<i>35</i>

<i>Biomarkers of nephrotoxicity</i> .....	36
<i>Cardiotoxicity</i> .....	37
<i>Neurotoxicity</i> .....	38
Biomarkers in clinical trials.....	38
<b>Molecular diagnostics</b> .....	<b>39</b>
Molecular imaging .....	39

### **3. Drug Monitoring Instruments ..... 41**

<b>Introduction</b> .....	<b>41</b>
<b>Description of important instruments</b> .....	<b>41</b>
AB SCIEX instruments .....	41
<i>AB SCIEX LC/MS/MS</i> .....	41
Abbott instruments .....	42
<i>ARCHITECT c16000</i> .....	42
<i>ARCHITECT c4000</i> .....	42
<i>ARCHITECT c8000</i> .....	42
<i>ARCHITECT ci16200 Integrated System</i> .....	43
<i>ARCHITECT ci4100 Integrated System</i> .....	43
<i>ARCHITECT ci8200 integrated with the ARCHITECT i2000SR</i> .....	43
<i>ARCHITECT i1000SR</i> .....	44
<i>ARCHITECT i4000SR</i> .....	44
<i>AxSYM</i> .....	45
Alfa Wassermann's ACE Alera .....	45
AMS Diagnostics' LIASYS .....	45
Awareness Technology's STAT FAX 4500 .....	45
Beckman Coulter instruments .....	46
<i>Beckman Coulter Unicel Series</i> .....	46
<i>AU5800 automated chemistry systems</i> .....	46
<i>AU480</i> .....	47
Binding Site ESP600 .....	47
bioMerieux Mini Vidas .....	48
Carolina BioLis 24i .....	48
Chromsystems' HPLC instruments .....	48
Grifols Triturus .....	48
ABX Pentra 400 .....	49
Medica EasyRA .....	49
<i>Nova Biomedical Critical Care Xpress</i> .....	49
Ortho Clinical Diagnostics' VITROS® family of systems .....	50
<i>Immunodiagnostic systems</i> .....	50
Randox instruments .....	51
<i>Randox RX Imola</i> .....	51
Roche instruments .....	51
<i>Cobas® 8000</i> .....	51
<i>COBAS INTEGRA® Systems</i> .....	51
Siemens instruments .....	52
<i>ADVIA 1200</i> .....	52
<i>ADVIA Centaur XP immunoassay system</i> .....	52
<i>EMIT® II Plus Syva®</i> .....	52
<i>Viva® Drug Testing Systems</i> .....	53
<i>Dimension® Xpand® Plus Integrated Chemistry System</i> .....	53
Thermo Scientific instruments .....	53
<i>Indiko</i> .....	53
Tosoh AIA-Series .....	53

### **4. Applications of TDM ..... 55**

<b>Introduction</b> .....	<b>55</b>
<b>Pharmaceutical research and drug development</b> .....	<b>55</b>
Clinical trials .....	55
Computerized clinical decision support systems for TDM and dosing .....	55
<b>TDM in special groups</b> .....	<b>56</b>
The aged .....	56
Children .....	56
Pregnancy .....	56
<b>TDM of prophylactic therapy</b> .....	<b>57</b>
TDM of vitamin D for fracture risk .....	57
<b>Personalized medicine</b> .....	<b>57</b>
Role of TDM in personalized medicine .....	57
<b>Applications according to various conditions</b> .....	<b>58</b>
Anesthesia and critical care .....	58
<i>Optimizing antimicrobial dosing for critically ill patients</i> .....	58
<i>TDM monitoring of thiopental continuous infusion in critical care</i> .....	58

<i>Role of TDM in critical care cardiac patients</i> .....	59
Cancer.....	59
Cardiovascular disorders .....	60
Epilepsy.....	60
<i>Personalized approach to use of AEDs</i> .....	60
Infections .....	61
<i>Virus infections</i> .....	61
<i>Fungal infections</i> .....	61
Inflammatory bowel disease.....	62
Pain .....	62
<i>Role of TDM in pain management</i> .....	62
<i>AEDs as analgesics</i> .....	62
Psychiatric disorders.....	62
Transplantation .....	63
Emergency toxicology.....	64
<b>Future prospects of TDM</b> .....	<b>64</b>

## **5. Drugs Requiring Monitoring ..... 65**

<b>Introduction</b> .....	<b>65</b>
<b>Antiepileptics</b> .....	<b>65</b>
Carbamazepine.....	65
<i>TDM of carbamazepine</i> .....	66
Lamotrigine.....	66
<i>TDM of lamotrigine</i> .....	66
Levetiracetam .....	67
<i>TDM of levetiracetam</i> .....	67
Phenobarbital .....	68
<i>TDM of phenobarbital</i> .....	68
Phenytoin .....	68
<i>TDM of phenytoin</i> .....	69
Primidone .....	69
<i>TDM of primidone</i> .....	69
Valproic acid.....	70
<i>TDM of valproic acid</i> .....	70
TDM of multiple antiepileptic drugs in plasma/serum .....	70
<b>Antimicrobials</b> .....	<b>71</b>
Antibiotics.....	71
<i>Amikacin</i> .....	71
<i>Anti-tuberculosis drugs</i> .....	71
<i>Chloramphenicol</i> .....	72
<i>Gentamicin</i> .....	72
<i>Tobramycin</i> .....	72
<i>Vancomycin</i> .....	73
<i>Norvancomycin</i> .....	73
Antiviral agents .....	73
<i>Anti-HIV drugs</i> .....	73
Antifungal agents.....	74
<i>Voriconazole</i> .....	74
<b>Antidepressants</b> .....	<b>74</b>
<b>Antipsychotics</b> .....	<b>74</b>
Quetiapine .....	74
TDM of risperidone.....	75
TDM of AEDs in psychiatric disorders .....	75
<b>Bronchodilators</b> .....	<b>75</b>
<b>Cardiovascular drugs</b> .....	<b>76</b>
Antiarrhythmic drugs.....	76
Antihypertensive drugs .....	76
<i><math>\beta</math>-blockers</i> .....	76
Cardiotonic drugs.....	76
<i>Digoxin</i> .....	76
<b>Chemotherapy for cancer</b> .....	<b>77</b>
Methotrexate.....	77
<b>Immunosuppressive drugs</b> .....	<b>77</b>
<i>TDM of tacrolimus</i> .....	77
<i>TDM of cyclosporine A-based immunotherapy in liver transplantation</i> .....	78
<i>TDM of mycophenolic acid in transplantation</i> .....	78
<b>Steroids</b> .....	<b>79</b>
Prednisone.....	79
<b>Miscellaneous drugs</b> .....	<b>79</b>
Sildenafil .....	79

<b>6. Monitoring of Biological Therapies.....</b>	<b>81</b>
<b>Introduction .....</b>	<b>81</b>
<b>Cell therapy .....</b>	<b>81</b>
In vivo tracking of cells.....	81
<i>Molecular imaging for tracking cells.....</i>	<i>81</i>
<i>MRI technologies for tracking cells .....</i>	<i>82</i>
<i>Superparamagnetic iron oxide nanoparticles as MRI contrast agents .....</i>	<i>83</i>
<i>Visualization of gene expression in vivo by MRI .....</i>	<i>83</i>
<b>Gene therapy .....</b>	<b>84</b>
<b>Application of molecular diagnostic methods in gene therapy .....</b>	<b>84</b>
Use of PCR to study biodistribution of gene therapy vector.....	84
PCR for verification of the transcription of DNA .....	85
In situ PCR for direct quantification of gene transfer into cells .....	85
Detection of retroviruses by reverse transcriptase (RT)-PCR.....	85
Confirmation of viral vector integration .....	85
Monitoring of gene expression .....	85
<i>Monitoring of gene expression by green fluorescent protein.....</i>	<i>86</i>
<i>Monitoring in vivo gene expression by molecular imaging.....</i>	<i>86</i>
<b>Monoclonal antibodies .....</b>	<b>87</b>
Natalizumab.....	87
<b>7. Monitoring of Drug Abuse .....</b>	<b>89</b>
<b>Introduction .....</b>	<b>89</b>
<b>Tests used for detection of drug abuse .....</b>	<b>90</b>
MS for doping control .....	90
Infrared attenuated total reflection spectroscopy for detection of drugs .....	90
Randox assays for DoA .....	91
Drugs of Abuse Array V .....	91
Urine drug testing .....	92
<b>TDM of drugs for treatment of substance abuse-related disorders .....</b>	<b>92</b>
<b>Drug testing to monitor treatment of drug abuse .....</b>	<b>92</b>
Minimum requirement for drug testing in patients .....	92
<b>Analgesic abuse.....</b>	<b>93</b>
<b>Chronic alcohol abuse.....</b>	<b>94</b>
<b>Cocaine.....</b>	<b>94</b>
CEDIA for cocaine in human serum .....	94
<b>Marijuana .....</b>	<b>95</b>
Use of marijuana and synthetic cannabinoids .....	95
Detection of cannabinoids .....	96
<i>ELISA for detection of synthetic cannabinoids.....</i>	<i>96</i>
<b>Drug abuse for performance enhancement in sports .....</b>	<b>96</b>
Historical aspects of drug abuse in sports.....	96
Drugs used by athletes for performance enhancement.....	97
Techniques used for detection of drug abuse by athletes.....	98
<i>Mass spectrometry for detection of peptide hormones .....</i>	<i>98</i>
<i>miRNAs for the detection of erythropoiesis-stimulating agents.....</i>	<i>98</i>
Body fluids and tissues used for detection of drug abuse in sports.....	98
<i>Urine drug testing .....</i>	<i>98</i>
<i>Spray (sweat) drug test kits.....</i>	<i>99</i>
<i>Hair drug testing.....</i>	<i>99</i>
<b>Limitations and future prospects .....</b>	<b>99</b>
<b>8. Markets for TDM .....</b>	<b>101</b>
<b>Introduction .....</b>	<b>101</b>
<b>Methods for market estimation and future forecasts .....</b>	<b>101</b>
Markets for TDM tests .....	101
Markets for TDM and DoA testing equipment .....	102
Geographical distribution of markets for TDM tests.....	102
Drivers for growth of TDM markets .....	103
Markets for DoA testing .....	104
<b>Unmet needs in TDM .....</b>	<b>104</b>
Cost-benefit studies .....	105
Simplifying assays and reducing time and cost .....	106
<b>Strategies for developing markets.....</b>	<b>106</b>
Physician education.....	107
Supporting research on TDM .....	107
<b>9. Companies .....</b>	<b>108</b>
<b>Profiles of companies.....</b>	<b>108</b>
<b>Collaborations.....</b>	<b>141</b>

**10. References..... 143**

**Tables**

Table 1-1: Historical landmarks in the development of therapeutic drug monitoring ..... 11  
Table 5-1: Indications and therapeutic ranges of various AEDs..... 65  
Table 6-1: Molecular imaging methods for tracking cells in vivo..... 82  
Table 6-2: Applications of molecular diagnostics in gene therapy ..... 84  
Table 7-1: Commonly tested drugs of abuse and recreational drugs..... 89  
Table 7-2: Testing and confirmation cutoff concentrations/detection times for DoA ..... 93  
Table 7-3: Historical landmarks of drug abuse in sports..... 96  
Table 7-4: Drugs used by athletes for performance enhancement..... 97  
Table 8-1: Global markets for TDM according to technologies from 2011-2021 ..... 102  
Table 8-2: Markets for TDM and DoA testing equipment ..... 102  
Table 8-3: Geographical distribution of markets for TDM tests..... 103  
Table 8-4: Drivers for growth of TDM markets..... 103  
Table 8-5: Global markets for DoA testing 2011-2021 ..... 104  
Table 9-1: Drugs for which monitoring and detection tests are provided by LabCorp ..... 124  
Table 9-2: Collaborations of companies involved in TDM..... 141

**Figures**

Figure 1-1: Therapeutic range of a drug ..... 14  
Figure 1-2: Flow chart of TDM ..... 16  
Figure 1-3: Interrelationships of TDM ..... 16  
Figure 2-1: Basic principle of a biosensor..... 26  
Figure 8-1: Unmet needs in TDM ..... 105